References
- Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study - The Lancet [Internet]. [cited 2020 Aug 26]. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32007-0/fulltext#%20.
- Chatelut E, White-Koning ML, Mathijssen RH, Puisset F, Baker SD, Sparreboom A. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br J Cancer. 2012; 107(7):1100–6.
- Plumridge RJ, Sewell GJ. Dose-banding of cytotoxic drugs: A new concept in cancer chemotherapy. Am J Health Syst Pharm. 2001; 58(18):1760–4.
- Koundalijan J. Setting up a CIVAS. In The CIVAS Handbook. 1st ed. London: London Pharmaceutical Press; 1998. p. 1–5.
- Soumoy L, Pirlot C, Decoster C, Gillet P, Hecq JD. Etude préliminaire pour l’implémentation d’un dose-banding de chimiothérapie anticancéreuse. Journal De Pharmacie De Belgique. 2015;97(3):24–35.
- Hecq JD. Centralized intravenous additive services (CIVAS): the state of the art in 2010. Ann Pharm Fr. 2011; 69(1):30–7.
- Pérez HP, Cueto SM, Escobar CP, Borrell GC, Albert MA, López BE, et al. Applying dose banding to the production of antineoplastic drugs: a narrative review of the literature. Farm Hosp. 2015;39(4):210–6.
- Lien K, Cheung MC, Chan KKW. Adjusting for drug wastage in economic evaluations of new therapies for hematologic malignancies: a systematic review. J Oncol Pract. 2016; 12(4):e369–e379.
- Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003; 3(5):330–8.
- Milano G, Etienne MC, Cassuto-Viguier E, Renée N, Bousselet M, Guillot T, Lecompte D. Long-term stability of 5-fluorouracil and folinic acid admixtures. Eur J Cancer. 1992;29A(1):129–32.
- Stiles ML, Allen LV, Tu YH. Stability of fluorouracil administered through four portable infusion pumps. Am J Hosp Pharm. 1989; 46(10):2036–40.
- Galanti L, Lebitasy MP, Hecq J-D, Cadrobbi J, Vanbeckbergen D, Jamart J. Long-term stability of 5-fluorouracil in 0.9% sodium chloride after freezing, microwave thawing, and refrigeration. Can J Hosp Pharm. 2009;62(1):34–8.
- Martel P, Petit I, Pinguet F, Poujol S, Astre C, Fabbro M. Long-term stability of 5-fluorouracil stored in PVC bags and in ambulatory pump reservoirs. J Pharm Biomed Anal. 1996; 14(4):395–9.
- Barberi-Heyob M, Watelet M, Merlin JL, Bleger C, Schroeder B. [Stability of 5-fluorouracil solutions according to different parameters]. Bull Cancer. 1995; 82(12):1025–31.
- Reinhardt H, Trittler R, Eggleton AG, Wöhrl S, Epting T, Buck M, Kaiser S, Jonas D, Duyster J, Jung M, et al. Paving the way for dose banding of chemotherapy: an analytical approach. J Natl Compr Canc Netw. 2017;15(4):484–93.
- Abraham J. International Conference on Harmonisation (ICH) of technical requirements for registration of pharmaceuticals for human use. In: Tietje C, Brouder A, éditeurs. Handbook of transnational economic governance regimes [Internet]. Brill| Nijhoff; 2010 [cité 16 mars 2020]. Disponible sur: https://brill.com/view/book/edcoll/9789004181564/Bej.9789004163300.i-1081_085.xml
- Lahlou A, Blanchet B, Carvalho M, Paul M, Astier A. Mechanically-induced aggregation of the monoclonal antibody cetuximab. Ann Pharm Fr. 2009; 67(5):340–52.
- Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs-A review. J Pharm Anal. 2014; 4(3):159–65.
- Pinguet F, Favre G, Canal P, Pujol A, Soula G. Stabilité des solutions de 5-fluoro-uracile à la chaleur et à la lumière. Journal de Pharmacie Clinique. 1990;9:155–8.